Picard Medical, Inc. · AMEX:PMI
Picard Medical — Shareholder Meeting (July 2026)
18 slides from Picard Medical's shareholder meeting presentation, Jul 2, 2026
Slide 1: 2026 Annual Stockholder Meeting
Oesuncardia WwW PICARD ‘Picard Medical Company NYSE: PMI 2026 Annual Stockholder Bus j SAVING LIVES, ONE HEART AT A TIME 3 e Picard Medical Inc. 's products are ap
Slide 2: Forward-Looking Statements
Forward-Looking Statements This Presentation contains statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can genera
Slide 3: Disclaimers
Disclaimers General: Picard Medical, Inc. (NYSE American: PMI) (the “Company”) is making this presentation available in connection with its 2026 Annual Meeting. Theinformation contained in this presentation does not purport to be complete or to contain all of the information that prospective investo
Slide 4: Driving Scalable Growth with an Experienced, Results-Focused Team
Driving Scalable Growth with an Experienced, Results-Focused Team Richard Fang, Ph.D. isthe Matt Schuster was appointed Georgina Smith was appointed founder and Managing Partner Chief Operating Officer in Chief Accounting Officer of Hunniwell Lake Ventures | November 2023 after serving as effective
Slide 5: Agenda
Agenda Agenda | Speak Dr. Richard Fang, Interim Chief Executive Officer Matt Schuster, Chief Operating Officer Welcome and Introductions 2026 Highlights Georgina Smith, Chief Accounting Officer Emperor Update Matt Schuster, Chief Operating Officer Voting Items Georgina Smith, Chief Accounting Office
Slide 6: To pioneer the future of heart replacement
To pioneer the future of heart replacement by providing the world’s first Total Artificial Heart and developing the next-generation system as an alternative to transplantation cincardia Brvrre
Slide 7: Key Achievements Year to Date through Q1 2026 10-Q Filing
Key Achievements Year to Date through Q1 2026 10-Q Filing Commercial Progress Pec on otoey) Manufacturing and Advancement Operations * Revenue increased ¢ Progress on next * Initiated transfer of key 85% YOY generation driver manufacturing steps ¢ Gross Margin increased technologies including in hou
Slide 8: Capitalization and Fully Diluted Share Count
Capitalization and Fully Diluted Share Count Total Shares Outstanding “) 92,349,845 Warrants (23) 7,710,280 Equity Incentive Plan 18,000,000 Fully Diluted Shares 118,060,125 Common Shares Authorized 300,000,000 Preferred Shares Authorized 30,000,000 (1)On May6, 2026, the Company completed a public o
Slide 9: Manufacturing Optimization
Manufacturing Optimization » Supports lower manufacturing cost » Reduces component obsolescence risk » Control key components Sources: Picard Medical in SEC ing § SynCardinSytamsLLC. ‘SynCardia’s products are approved for sale in the U.S. and Canada only. Ocuncardia ‘SinCardia Geter, LLCIS@ wholly o
Slide 10: Emperor Total Artificial Heart (ETAH)
Emperor Total Artificial Heart (ETAH) * Development ofa platform to a fully implantable artificial heart designed to eliminate external pneumatic drivers * The Emperor Total Artificial Heart consists of the Emperor Drive System and SynCardia Total Artificial Heart (STAH) « Preserves surgical placeme
Slide 11: Development Roadmap
Development Roadmap 2026 ~ Submission for FDA Breakthrough Device Designation ~— Continued acute animal studies — Design iteration and reliability testing 2027 — Design freeze ~ Initiation of Good Lab Practice (GLP) animal studies 2028 ~— Completion of verification and validation testing ~ Submissio
Slide 12: Items for Stockholder Approval
Items for Stockholder Approval 1. Election of Directors Reverse Stock Split Authorization Creation of Class B Common Stock Ratification of Independent Auditor Advisory Approval of Executive Compensation BS 2: Be @ Advisory Vote on Frequency of Executive Compensation Votes Ssurcen: Poard Medical in S
Slide 13: Election of Directors
Election of Directors New elections Dr. Joe Guohua Xiao (57)- Founder and CEO of AnX Robotica and ANKON Technologies, Dr. Xiao is a serial medtech entrepreneur and inventor with 50+ patents, known for pioneering magnetically controlled capsule endoscopy and Al-driven gastrointestinal diagnostics. He
Slide 14: Amendment to Authorize a Reverse Stock Split
Amendment to Authorize a Reverse Stock Split Summary Provide our Board with the authority (but not the obligation) to effect a reverse stock split of our outstanding Common Stock (the “Reverse Stock Split”) Purpose * To provide the Board with flexibility to address market and capital markets conside
Slide 15: Amendment to Create Class B Common Stock
Amendment to Create Class BCommon Stock Summary The Board is seeking stockholder approval to amend the Certificate of Incorporation to authorize a new Class B Common Stock with 20 votes per share (vs. one vote per share for existing common stock), to be issued at the Board’s discretion. Purpose * To
Slide 16: Additional Stockholder Voting Items
Additional Stockholder Voting Items Ratification of Independent Auditor: Stockholders are being asked to ratify the appointment of the Company’s independent registered public accounting firm for the current fiscal year. Advisory Approval of Executive Compensation: Stockholders are being asked to app
Slide 17: Meeting of Stockholders
Meeting of Stockholders July 17, 2026 at 6:00 pm ET The Annual Meeting will be held entirely online at https://www.cstproxy.com/picardmedical/am2026. OO sincardia Brvrre
Slide 18: SynCardia Systems, LLC
> —N XP SynCardia Systems, LLC 1992 E. Silverlake Rd. Tucson, AZ 85713 | US +1 520-545-1234 | info@syncardia.com www.SynCardia.com NYSE: PMI SynCardia's products are approved for sale in the U.S. and Canada only. fegistered trademark of SynCa ving Lives, one Heart at a Time Systems, LLC. “SynCardia